Key Highlights
- Shares trading down 22.77% pre-market to $11.70, extending Wednesday's 4.87% regular-session decline
- Q2 2026 Revenue of $131.1 million, up 16% year-over-year, narrowly missed the $131.9 million consensus estimate
- Company lowered full-year 2026 ARR guidance to $550 million to $560 million and revenue guidance to $555 million to $561 million
- Raised full-year 2026 Adjusted EBITDA target despite the lowered top-line outlook
- Announced Shiven Ramji as new CEO, succeeding Thomas E. Hogan effective immediately
- Annual Recurring Revenue reached $507.8 million, up 21% year-over-year, though management said ARR came in below expectations
Shares Extend Decline on Lowered Guidance
Cellebrite (NASDAQ:CLBT) shares are plunging in pre-market trading Thursday, down 22.77% to $11.70, extending Wednesday's 4.87% regular-session decline after the digital forensics firm reported second-quarter results that narrowly missed consensus alongside soft forward guidance. Revenue reached $131.1 million, up 16% year-over-year, but came in just below the $131.9 million estimate, while the company lowered its full-year 2026 ARR and revenue outlook even as it raised its Adjusted EBITDA target.
Cellebrite DI Ltd. is a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, headquartered in Tysons Corner, Virginia and Petah Tikva, Israel. More than 7,000 global law enforcement agencies, defense and intelligence organizations, and enterprises trust Cellebrite's AI-powered software portfolio to make forensically sound digital data more accessible and actionable, accelerating nearly 3 million legally sanctioned investigations annually through flagship products including the Universal Forensic Extraction Device, Guardian, and Cellebrite Genesis.
Guidance Cut Reflects Slower ARR Conversion
"We delivered healthy second-quarter growth in Asia-Pacific, EMEA and U.S. Federal," said newly appointed CEO Shiven Ramji. "However, ARR came in below our expectations. We saw longer sales cycles and less expansion from Inseyets conversions than anticipated. We are taking action to improve execution going forward." Annual Recurring Revenue reached $507.8 million, up 21% year-over-year, with a recurring revenue dollar-based net retention rate of 117%, up 2 points over the first quarter.
Given these dynamics, the company lowered its full-year 2026 ARR guidance to $550 million to $560 million and revenue guidance to $555 million to $561 million, while raising its Adjusted EBITDA target to $153 million to $159 million, citing continued operating discipline. For the third quarter, the company guided to ARR of $524 million to $528 million and revenue of $145 million to $148 million.
Leadership Transition Adds to Investor Uncertainty
The company also announced that Shiven Ramji, who joined Cellebrite as President, Products and Technology in May 2026, has succeeded Thomas E. Hogan as CEO effective immediately, as part of a planned transition. "Shiv's succession is the clearest proof of his success in this endeavor," said Adam Clammer, Chairman of Cellebrite's Board of Directors, referring to Hogan's work building the Leadership team. The combination of the guidance cut and simultaneous leadership change appears to be compounding investor uncertainty already weighing on the stock following the disappointing near-term outlook.
Conclusion
Cellebrite's 22.77% pre-market decline reflects investors digesting a lowered full-year ARR and revenue outlook alongside an unexpected CEO transition, even as the company posted double-digit revenue growth and raised its profitability target. With longer sales cycles and slower Inseyets conversion cited as the primary culprits behind the guidance cut, the stock's next moves will likely hinge on new CEO Shiven Ramji's ability to improve execution in the back half of the year.






Please wait processing your request...